All News
Filter News
Found 8,090 articles
-
Mana.bio Advances AI-Based Lipid Nanoparticle (LNP) Platform to Accelerate "Programmable Drug Delivery" for RNA and Gene Therapies
10/10/2023
Mana.bio, a biotechnology company accelerating programmable drug delivery, unveiled its AI-based lipid nanoparticle delivery platform to accelerate the development of nucleic acid-based therapeutics and vaccines.
-
Kexing Biopharm Holds China-MENA & South Asia Pharmaceutical Cooperation High-end Forum, Aiming at Foreign Emerging Markets
10/9/2023
The 2023 China-MENA & South Asia Pharmaceutical Cooperation High-end Forum and Kexing Biopharm's Series of Globalization Activities were successfully held recently.
-
Axion BioSystems Welcomes Biotech Industry Leader Julien Bradley as New CEO
10/5/2023
Axion BioSystems today announced the appointment of Julien Bradley as the company’s new Chief Executive Officer.
-
Here’s how some biopharmas have managed to gain funding despite a falloff in investment in the sector. Hint: Positive late-stage data is a key factor.
-
Starton Therapeutics Doses First Patient in Landmark STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma
10/4/2023
Starton Therapeutics Inc. announced the dosing of the first patient in the STAR-LLD Phase 1b clinical trial, which will assess the safety, efficacy and pharmacokinetics of continuous subcutaneous administration of low-dose lenalidomide (STAR-LLD) for the treatment of multiple myeloma (MM).
-
Syneos Health Appoints Colin Shannon as Chief Executive OfficerIndustry Veteran Brings Decades of Experience Driving Growth at Global Biopharmaceutical Solutions Organizations
10/3/2023
Syneos Health, Inc., a leading fully integrated biopharmaceutical solutions organization, announced that Colin Shannon has been appointed Chief Executive Officer, effective immediately.
-
Despite a sharp downturn in initial public offering activity, New York-based gene therapy company Lexeo Therapeutics and French biotech Abivax are seeking funding for their lead candidate programs.
-
Newron Appoints Margarita Chavez as Board Advisor
10/2/2023
Newron Pharmaceuticals S.p.A. announced that Margarita Chavez has been appointed as an advisor to the Board of Directors of Newron, bringing significant pharmaceutical business development and dealmaking expertise.
-
Danaher Corporation Completes Separation of Veralto Corporation
9/30/2023
Danaher Corporation announced that it has completed the separation of its Environmental & Applied Solutions segment, through the spin-off of Veralto Corporation.
-
Renalytix Reports Full Year Fiscal 2023 Results
9/28/2023
Renalytix plc, an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, reports its financial results for the fiscal year ended June 30, 2023.
-
OncoC4 Strengthens Leadership Team with the Appointment of Abid Ansari as Chief Financial Officer
9/28/2023
OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer, announced the appointment of Abid Ansari as Chief Financial Officer, effective immediately.
-
PureTech Announces the Appointment of Robert Lyne as Chief Portfolio Officer
9/27/2023
PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, announced the appointment of Robert Lyne as Chief Portfolio Officer.
-
Faron Pharmaceuticals Announces Board Changes - September 22, 2023
9/22/2023
Faron Pharmaceuticals Ltd. is pleased to announce the appointment of Ms. Christine Roth and Dr. Marie-Louise Fjällskog as Non-Executive Directors of the Company with immediate effect following the passing of all resolutions put to shareholders of the Company at the Extraordinary General Meeting held earlier.
-
Seraxis Announces Closing of Second VC Tranche and Successful Completion of Preclinical Studies of Pancreatic Organoids From Seraxis’ Novel Pancreas-Derived Stem Cells
9/21/2023
Seraxis Inc today announced the closing of the second tranche of its inaugural VC round to bring total equity investment in the company to over $50 million.
-
Lynk Pharmaceuticals Completes Series C2 Financing Round, with Total C Round Funding of 322 Million RMB
9/21/2023
Lynk Pharmaceuticals Co., Ltd. today announced the successful completion of Series C2 financing.
-
Abpro to Become Publicly Traded via Merger with Atlantic Coastal Acquisition Corp. II
9/21/2023
Abpro Corporation and Atlantic Coastal Acquisition Corp. II announced a term sheet to enter into a definitive business combination, which was entered into on September 18, 2023.
-
After a sluggish start to the year, experts expect an uptick in IPO offerings moving into fall, although it’s unlikely 2023 will fully shrug off its slump.
-
Cayman Chemical Receives CEP for Latanoprost API from EDQM
9/19/2023
Cayman Chemical, a world leader in the manufacture of prostaglandins for both research use and as active pharmaceutical ingredients
-
RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
9/19/2023
RayzeBio, Inc. (Nasdaq: RYZB) today announced the closing of its previously announced upsized $358 million initial public offering (IPO) of 19,869,240 shares of common stock, including the full exercise of the underwriters’ option to purchase up to 2,591,640 additional shares from RayzeBio, at a price to the public of $18.00 per share.
-
In the largest biotech Series C financing so far this year, Generate:Biomedicines raised $273 million, while Neumora and RayzeBio announced IPO pricing valued at more than $560 million combined.